What are we treating with opioid and sedative–hypnotic combination therapy?

M. Sullivan

DOI: https://doi.org/10.1002/pds.3821

2015-08-01

Pharmacoepidemiology and Drug Safety

Abstract:For the past two decades, we have witnessed dramatic increases in the prescription,misuse, and abuse of opioid analgesics. There are now multiple indications that we have passed the peak inprescriptionopioiduse and abuse in the USA. However, Larochelle and colleagues report that we have not yet seen a decline in the concurrent prescription of opioids and benzodiazepines (BZ) or other sedative–hypnotics.1 This remains an urgent public health problem. They examined data from cross-sectional surveys from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey over the period from 2001 to 2010. These include visits to clinics and to outpatient departments of hospitals. The authors examined visits where the patient’s primary reason for the visit was musculoskeletal pain. These are the most common pain complaints presented in ambulatory care. Visits for acute pain (onset within 3months of visit) were distinguished from visits for chronic pain. The risks and benefits of opioid therapy are quite different for acute and chronic pain, so this distinction is appropriate. The primary outcome of interest was a new or continuing prescription for an opioid during a visit. The study thus examines all opioid prescribing and is not limited to long-term opioid therapy. Opioid prescription during acute pain visits increased during the study period from 10.4% of visits in 2001 to 15.6% of visits in 2010. Opioid prescribing during chronic pain visits increased from 2001 (13% of visits) to 2007 (28% of visits) but then declined to 2010 (23% of visits). This is an earlier peak than that described by Dart et al. in their New England Journal of Medicine article,2 but it is consistent with other state-based data on recent declines in opioid prescribing and deaths.3 The article by Larochelle and colleagues adds to the literature by examining the co-prescribing of opioids and BZ or sedative–hypnotics. This co-prescribing adds substantially to the risk of respiratory depression and death for the patient. Accidental opioid-related deaths increased by fourfold between 1999 and 2009. It has been reported that 75% of deaths from pharmaceutical agents involved opioids, while 29% involved BZs.4 Calcaterra et al. reported that prescription opioidrelated deaths commonly involve alcohol, sedatives, and/or illicit drugs. The most common fatal combination was opioids and BZs.5 Investigators have estimated that as many as 80% of unintentional overdose deaths involving opioids may involve BZs.6 Despite these risks, Larochelle and colleagues report that BZ prescribing is more likely when opioids are prescribed. It is three times more likely during acute pain visits and four times more likely during chronic pain visits. Larochelle and colleagues examine a narrow definition of sedatives that includes only BZs and a broad definition of sedatives that includes BZs, “muscle relaxants,” and the partial agonist z-drugs. This is important, because the rates of co-prescribing for the narrow and broad classes differ significantly. Among patients prescribed opioids, 8% also received a BZ during an acute pain visit and 15% received a BZ during a chronic pain visit. But among patients prescribed opioids, 33% received a sedative during an acute pain visit, and 36% received a sedative at a chronic pain visit. Notably, for those receiving both opioid and sedative at a chronic pain visit, 39% received a BZ, 73% a muscle relaxant, and 7% a z-drug. The skeletal muscle relaxants used in the care of musculoskeletal pain are a heterogeneous group of *Correspondence to: M.D.Sullivan,Psychiatry andBehavioral Sciences,University of Washington, 1959 NE Pacific St., Seattle, WA, USA. E-mail: sullimar@uw.edu

Medicine